The Daily Brief

November 05, 2026

Maryland officials launched a process Thursday allowing firefighters and rescue workers employed in the state but living out-of-state to register as medical cannabis patients, fulfilling a law signed by Gov. Wes Moore in April that protects first responders from employment discrimination for lawful off-duty marijuana use. The Maryland Cannabis Administration said the registration pathway for interstate workers is "forthcoming," while out-of-state employees can currently fill out an interest form to be notified when applications open. The law, which took effect October 1, covers firefighters, EMTs, and paramedics employed by municipal corporations and state agencies, protecting them from retaliation for testing positive for cannabis metabolites if they hold a valid medical certification—though certifications must come from Maryland-registered providers, not out-of-state doctors.

Wisconsin Democrats are moving fast on legalization following Tuesday's midterm sweep that gave the party full control of the legislature for the first time in 16 years. Rep. Greta Neubauer, poised to become Assembly speaker, said the state will legalize marijuana "in the coming year to two years," while Sen. Mark Spreitzer called himself "very optimistic" about passage. Money Both lawmakers highlighted the fiscal argument: Wisconsin currently sees an estimated $40 million in cannabis tax revenue flowing across state borders to Illinois dispensaries just miles from communities like Beloit, and incoming Gov. David Crowley has discussed using legalization revenue to fund education and healthcare. Gov.-elect Crowley told a debate audience last month that "we have to go towards full legalization because this is opportunity that we're missing out on as a state."

Bipartisan signals are emerging at the federal level as well. Democratic Rep. Dina Titus of Nevada, co-chair of the Congressional Cannabis Caucus, told Marijuana Moment she will "continue fighting for commonsense cannabis policy reform," while Republican operative Roger Stone—a longtime Trump senior campaign aide—said he would urge President Trump to sign marijuana legislation that the Democratic-controlled Congress sends him. Sen.-elect James Talarico, a Texas Democrat who won a high-profile race, announced Wednesday that he plans to "work with Trump on federally legalizing marijuana," noting that both he and the president support legalization. Stone criticized past Democratic Congresses for inaction on criminal justice reform but said he's watching to see if Democrats will now "decriminalize marijuana at a minimum and deschedule at a maximum."

Houston voters approved a ballot measure Tuesday directing the police department to deprioritize misdemeanor cannabis possession charges and ban no-knock warrants for such cases—a reform mirroring measures already passed in Austin, Dallas, Killeen, and San Marcos. The move comes after arrests for low-level cannabis possession spiked nearly 1,200% under Mayor John Whitmire, with an average of 440 arrests per year compared to roughly 35 annually from 2021 to 2023. Whitmire has blamed prosecutors in the Harris County District Attorney's Office, though DA Sean Teare said his office is bound by state law. Context Texas hemp and cannabis businesses celebrated the ousting of Lt. Gov. Dan Patrick in the elections, signaling industry optimism about the state's policy direction despite current restrictions.

Georgia regulators announced Thursday that they will open a five-day dispensary application period from November 16 to 20, expecting the state's medical marijuana patient registry to reach 65,000 soon. As of September, Georgia had 56,650 active medical patients, representing explosive growth from 36,703 in June—an expansion that followed the July 1 implementation of the Putting Georgia's Patients First Act, which added qualifying conditions and allowed patients to access flower and concentrated products. Notable Under state law, reaching the 65,000-patient milestone would allow up to 60 dispensaries statewide, up from the current possible 54, as each of the six licensed producers gains access to a tenth dispensary location.

A Romanian court overturned rapper Wiz Khalifa's nine-month prison sentence for smoking marijuana onstage at a music festival in 2024, annulling the conviction issued in December 2025 and canceling the enforcement warrant. The Bucharest Court of Appeal granted Khalifa's legal challenge Tuesday; a new hearing is scheduled for November 12 when prosecutors will have another opportunity to argue for punishment. Khalifa, who was detained briefly after his July 2024 performance at the Beach, Please! Festival in Costinești and charged with possessing 18.5 grams of marijuana, initially received a fine of approximately $830, which was later upgraded to nine months imprisonment after prosecutors with the Directorate for Investigating Organized Crime and Terrorism appealed. Marijuana remains illegal for recreational use in Romania, where possession for personal consumption carries criminal penalties including imprisonment.

November 05, 2026

Trulieve Returns to Profitability with $230 Million in Q3 Revenue as Medical Cannabis Operations Accelerate Nationwide. The largest U.S. cannabis retailer reported a 64% gross margin and swung to $869,000 in net income, reversing a $26.8 million loss in the same quarter last year. Money The company generated $74.4 million in operating cash flow and $45.4 million in free cash flow during the quarter, ending September with $326.7 million in cash—up from $255.5 million at year-end 2025. Customer traffic increased 3% year-over-year while products sold rose 6%, with retail operations accounting for 95% of quarterly revenue at $219.3 million. Trulieve now operates 208 dispensaries nationwide, including 170 in Florida, and reported a sevenfold surge in Georgia customer traffic following the state's expansion of its medical marijuana program on July 1. CEO Kim Rivers attributed the turnaround partly to federal rescheduling of qualifying medical marijuana operations, which unlocked DEA registration, removal of the 280E tax burden, and NYSE uplisting—fundamentally reshaping the company's tax position and operational feasibility.

Across the competitive landscape, Money Organigram acquired Aurora Cannabis in a $401 million all-stock deal, ending Curaleaf's hostile takeover bid. Organigram will pay $5.57 per share, representing a 93% premium to Aurora's unaffected share price in August and a 21% premium to Curaleaf's unsolicited offer as of November. Aurora shareholders will hold approximately 35% pro forma economic ownership and 42% voting ownership of the combined entity, positioning the merged company to accelerate international growth and R&D capabilities. Meanwhile, Kiva Sales & Service and Petalfast launched Waveform, California's largest full-service cannabis distributor, with a technology-forward platform spanning 48 leading brands and 975 active retail stores. Green Thumb Industries opened its 27th Florida dispensary in Mulberry, expanding its nationwide RISE network to 130 locations across 14 markets, while Verano opened its 87th Florida dispensary in Fernandina Beach, bringing its nationwide total to 164 stores.

State-level momentum continued to reinforce market normalization. Notable Massachusetts voters decisively rejected Question 8, the ballot measure that would have dismantled the state's recreational cannabis market—75.69% opposed the repeal compared to 53.66% support for legalization a decade earlier. The rejection marked the first time U.S. voters were asked to undo an existing recreational cannabis industry, and the decisive 22-point swing reflects both consumer confidence in regulated markets and industry maturation. In Utah, medical marijuana sales hit a record $17.9 million in October, bringing year-to-date revenue to $166.4 million—14% above the same 2025 period. The state now has 118,238 active patient cardholders, up 13,552 from October 2025, with persistent pain remaining the predominant qualifying condition across more than 103,000 patients.

Context These developments converge on a single narrative: the cannabis business is consolidating at scale, generating genuine profits under federal rescheduling, expanding into new geographies, and proving durable against political reversal once markets mature and consumers experience regulated access firsthand.

November 05, 2026

Texas Political Earthquake Reshapes Hemp Industry as Federal Ban Deadline Looms

Democratic State Rep. Vikki Goodwin's defeat of incumbent Lt. Governor Dan Patrick in Tuesday's Texas election marks a dramatic shift for one of America's most contentious hemp battlegrounds. Patrick, who spearheaded restrictions on THC-containing hemp products since 2025, leaves office as Goodwin prepares to assume the state Senate presidency—a position with substantial legislative power. Shayda Torabi, whose company Restart CBD + THC was among Texas's first licensed retail hemp operations in 2019, described the election as breathing room: "I think we were all holding our breath...just knowing what we've dealt with, specifically with Dan Patrick over these past sessions." Patrick's signature achievement was forcing state agencies to implement rules banning smokeable THCA flower, hiking licensing fees, and restricting marketing—moves a Texas Supreme Court ruling later reinforced by reclassifying delta-8 and delta-10 as controlled substances. Torabi estimates those bans forced her to remove 50-60% of her inventory from shelves. Money The restrictions devastated what had become a substantial state industry built on the federal 2018 hemp legalization that preceded state adoption.

Goodwin's campaign explicitly promised to reverse those restrictions, pledging to "go back to where we were prior to DSHS implementing those new rules and then we'll address it through legislation." Industry advocates including Sarah Todd, director of the Texas Cannabis Policy Center, characterized the Democratic sweep—which also appears to have flipped the Texas House by at least one seat—as "huge" for sensible policy. Todd cautioned that exact policy mechanisms remain unclear, but predicted rollback of recent hemp rules. Goodwin also supports legalizing recreational marijuana, noting in her candidate questionnaire that "adults are already using them, and banning them will not change that. It will only push the market underground, where products are less safe and there is no accountability." The Texas Senate retained its Republican majority, meaning any legislative changes will require bipartisan support.

Nationally, the hemp industry faces a December 11 federal deadline that could eliminate most intoxicating hemp products sold outside state-licensed dispensaries. Money Total Wine & More has escalated its lobbying operation, newly registering Impact Management Group as a federal advocacy firm and reporting $510,000 in hemp-THC beverage lobbying expenditures through the first nine months of 2026—an amount that increased each quarter. The company backs the Beverage Regulatory Parity Act (H.R. 10079), bipartisan legislation that would allow hemp-derived beverages containing up to five milligrams of THC per serving, subject to age restrictions, testing, and three-tier distribution requirements. Under current law, finished hemp products containing more than 0.4 milligrams of total THC per container will lose federal legal status on December 11, threatening an estimated $700 million Wisconsin market alone—where companies like Kind Oasis are already preparing to operate in legal gray zones by relying on state law protections despite federal prohibition.

Wisconsin hemp businesses consulting attorneys, banks, and insurers have determined they can continue selling low-THC products as long as they remain below the state threshold and operate within state boundaries, according to Kind Oasis spokesperson Jason Handal. The Wisconsin Legislative Council noted in May 2026 that federal hemp restrictions "do not directly affect the legality of hemp under state law," but acknowledged that "industry participation will depend on risk tolerance by stakeholders and the manner in which enforcement of federal controlled substances laws is prioritized." Hemp attorney Jason Tarasek observed that Wisconsin would essentially join 41 states that legalized marijuana before federal law aligned—"It'd be shocking if the government took steps to crack down on that," he said. Context Illinois Governor JB Pritzker, despite having legalized recreational marijuana in 2019, recently called on Congress to let the federal ban proceed on schedule, positioning intoxicating hemp products outside his state's regulated licensed market.

South Korea's minister of SMEs and startups pledged to review hemp regulations to "support emerging industries while maintaining safety controls," signaling potential commercial expansion in Asia's regulatory landscape. In Tennessee, fraudulent emails claiming the Alcoholic Beverage Commission had lifted all THCA restrictions circulated to retailers before the agency confirmed it had been "hacked"—none of the claims were accurate and all existing restrictions remain in effect. Meanwhile, Notable a new scientific review published in the Journal of Cannabis Research found that marijuana terpenes and minor cannabinoids influence pain signaling through multiple biological pathways beyond traditional cannabinoid receptors, with certain compounds inhibiting calcium influx in pain-sensing neurons and others activating adenosine and CB2 receptors. Imperial College London researchers emphasized that marijuana's hundreds of naturally occurring constituents—THC, CBD, over 100 minor cannabinoids, and comparable terpenes—remain substantially understudied despite growing evidence of biological activity supporting full-spectrum preparations over isolated compounds.

November 05, 2026

Research published today in Cerebral Cortex reveals that cannabidiol strengthens brain connectivity in children with autism, marking a significant advance in understanding how cannabinoids influence neurological function. Conducted by researchers at Deakin University and Swinburne University of Technology in Australia, the study examined 18 children ages 5 to 12 who received either CBD oil or placebo in a randomized, double-blind trial. Notable After 12 weeks of CBD treatment—dosed between 5 and 10 milligrams per kilogram of body weight daily—children showed statistically significant increases in functional connectivity between the right frontal and right inferior-parietal regions of the brain, with a P-value of 0.001 and an effect size of 0.90. These regions govern attention, cognitive control, and social processing, areas where previous research has documented differences in autistic brain function. The placebo group showed no comparable improvement, underscoring the specificity of the CBD effect.

In parallel developments across the Atlantic, a Swiss study published in Drug and Alcohol Dependence documents an unexpected finding: adults with regulated access to legal marijuana experienced significant declines in depression, anxiety, and problematic use patterns over one year. The research followed 374 regular cannabis consumers purchasing products through licensed pharmacies under Switzerland's controlled framework—products limited to 20% THC with monthly purchase caps of 10 grams. Depression scores fell from 5.37 to 4.53 on average; anxiety symptoms decreased significantly; and the proportion of participants meeting clinical thresholds for cannabis use disorder dropped from 32.7% to 28.6%, though this latter change didn't reach statistical significance. Context Consumption frequency increased modestly, yet the quantity consumed remained stable, suggesting that legal access didn't trigger the escalated use some regulators feared.

The Swiss finding carries particular weight because it directly contradicts claims that legalization drives problematic consumption upward. Researchers emphasized that improvements in mental health were not attributable to increased use—consumption patterns stayed relatively flat—and that regulated access itself showed no association with worsening psychiatric outcomes. The improvements were most pronounced among participants who began the study with higher baseline problematic-use scores, suggesting that structured legal access may actually help high-risk users stabilize their relationship with the substance. Because the study lacked an untreated comparison group, causality remains uncertain; however, the data show that legal frameworks did not produce the negative mental health trajectory prohibition advocates routinely predict.

On the policy and academic front, the Global Cannabinoid Research Center has launched a healthcare sector survey as U.S. cannabis policy enters what multiple sources describe as a historic transition. The timing reflects documented shifts in Congress following the 2024 elections: Democrats control both Senate and House, and multiple states have elected governors and legislatures pledging to legalize medical or adult-use cannabis in 2027. Western Illinois University is preparing a "Cannabis & Culture in Amsterdam" study abroad course for May 2027, signaling growing academic legitimacy for cannabis policy and commerce as fields of study. Money These institutional moves suggest cannabis is transitioning from regulatory gray zone to established sector requiring specialized healthcare training and research infrastructure.

The CBD and cannabis science stories converge on a single emerging reality: controlled, research-grade cannabinoid formulations are producing measurable clinical outcomes in real populations. The Australian autism study used standardized dosing, EEG measurement, and rigorous design. The Swiss study tracked mental health metrics across months of legal access. Neither study claims cannabis is a cure-all; both document specific, modest improvements in defined patient populations under controlled conditions. These are the kinds of peer-reviewed, double-blinded datasets that build the evidence base for any therapeutic agent—alcohol and prescription opioids included, though neither faced the research restrictions cannabis has endured under Schedule I classification.